New European initiative to accelerate drug discovery for cardiometabolic diseases
7 Articles
7 Articles
BT
Kristeligt DagbladThe Novo Nordisk Foundation is investing 450 million kroner in an initiative to strengthen the innovation environment among researchers.
Novo Nordisk Foundation launches €60.2m European incubator for cardiometabolic drug discovery - European Biotechnology Magazine
The Novo Nordisk Foundation is launching a new European incubator network to turn academic discoveries in cardiometabolic disease into drug development projects, extending the broader European innovation push it set in motion earlier this year through a DKK5.5bn (€736 million) commitment to the BioInnovation Institute (BII). The post Novo Nordisk Foundation launches €60.2m European incubator for cardiometabolic drug discovery appeared first on E…
Novo Nordisk Foundation: New European initiative to accelerate drug discovery for cardiometabolic diseases
The Novo Nordisk Foundation is funding a new pan-European initiative to accelerate drug discovery and the development of next generation therapeutics for cardiometabolic diseases (CMDs). The initiative addresses one of today’s most pressing global challenges: Translating promising research into improved care for people living with CMDs. Despite Europe’s strong position in CMD research, many promising […] The post Novo Nordisk Foundation: New Eur…
Novo Nordisk, the main owner of the Ozempic manufacturer, is launching a network of research incubators across Europe, with the aim of creating innovative treatments against obesity and diabetes, transforming academic discoveries into commercial projects.The CardioMetabolic Bridge program will open its first headquarters in London this month, followed by others in Italy and Germany later this year, according to a statement from the Novo Nordisk …
Coverage Details
Bias Distribution
- 67% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
